Modality
Radioligand
MOA
GLP-1ag
Target
WRN
Pathway
Cell Cycle
Breast CaHCCThymoma
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
Dec 2018
→ Jun 2025
Phase 1Current
NCT06231262
23 pts·Breast Ca
2018-12→2025-06·Recruiting
23 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-159mo agoPh2 Data· Breast Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2025-06-15 · 9mo ago
Breast Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06231262 | Phase 1/2 | Breast Ca | Recruiting | 23 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET |